DEVELOPING: AstraZeneca Agrees to Historic White House Deal to Slash Drug Prices

Breaking News: AstraZeneca Agrees to Historic White House Deal to Slash Drug Prices AstraZeneca, a leading pharmaceutical company, has reached a landmark agreement with the White House to significantly lower drug prices for Medicaid and consumers. The deal, announced on October 10, 2025, marks the second major price-cutting agreement between a drugmaker and the Trump administration. Critical Details: AstraZeneca will offer most-favored-nation pricing for drugs sold to Medicaid, linking prices to lower rates paid in other developed countries. The company will also provide discounts of up to 80% off list prices on direct sales to consumers through the government's TrumpRx website. Immediate Impact: The agreement is expected to have a significant impact on patients and taxpayers. By reducing prices for Medicaid, the deal could save millions of dollars in healthcare costs. Additionally, the discounted prices offered directly to consumers will make essential medications more affordable for those who need them most. Background Context: This deal follows a similar agreement between Pfizer and the White House earlier this year. AstraZeneca's CEO, Pascal Soriot, shook hands with President Trump in the Oval Office on Friday, marking the culmination of months of negotiations. Current Status and Next Developments: The details of the agreement are still being finalized, but it is expected to be implemented in the coming weeks. The White House has not yet announced a timeline for when the discounted prices will become available through TrumpRx. This is a Developing Story: As more information becomes available, we will provide updates on this breaking news story. Stay tuned for further developments and analysis of the impact of this historic deal on the healthcare industry. *This is a developing story. Updates will be provided as more information becomes available. Based on reporting from Npr.*